Drug Profile
Research programme: isoflavonoid based cancer therapeutics - Noxopharm
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Noxopharm
- Class Antineoplastics; Isoflavones; Small molecules
- Mechanism of Action Caspase stimulants; NADH oxidase inhibitors; Proto oncogene protein c-akt inhibitors; X-linked inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Cancer in Australia (unspecified route)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Cancer in Australia